Journal article

CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer

Jiachen Xuan, Richard B Pearson, Elaine Sanij

MOLECULAR & CELLULAR ONCOLOGY | TAYLOR & FRANCIS INC | Published : 2020

Abstract

Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general mechanism of chemotherapeutic resistance.